INT 0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy

Bruce D. Minsky, Thomas F. Pajak, Robert J. Ginsberg, Thomas M. Pisansky, James Martenson, Ritsuko Komaki, Gordon Okawara, Seth A. Rosenthal, David P. Kelsen

Research output: Contribution to journalArticle

1078 Scopus citations

Abstract

Purpose: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer. Patients and Methods: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m2/24 hours for 4 days) and cisplatin (75 mg/m2 bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive. Results: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31% v 40%), or local/regional failure and local/regional persistence of disease (56% v 52%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less. Conclusion: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalJournal of Clinical Oncology
Volume20
Issue number5
DOIs
StatePublished - Mar 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'INT 0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy'. Together they form a unique fingerprint.

  • Cite this

    Minsky, B. D., Pajak, T. F., Ginsberg, R. J., Pisansky, T. M., Martenson, J., Komaki, R., Okawara, G., Rosenthal, S. A., & Kelsen, D. P. (2002). INT 0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. Journal of Clinical Oncology, 20(5), 1167-1174. https://doi.org/10.1200/JCO.20.5.1167